Reports Q4 revenue $99.7M, consensus $109.05M.Adjusted EBITDA of $7.5M for the fourth quarter of 2023, compared to Adjusted EBITDA of $14.1M for the fourth quarter of 2022, a decrease of $6.6 M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ORGO:
- Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
- Organogenesis Holdings (ORGO) Q4 Earnings Cheat Sheet
- Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
- Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024
- Organogenesis initiated with an Overweight at Cantor Fitzgerald